Tags: lung | disease | drug | astrazeneca | pt1003

Lung Disease Drug Proves Effective in Trials

Wednesday, 18 Mar 2015 08:34 AM

AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials.
 
The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago, combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA).

AstraZeneca plans to file PT003 for approval commencing in 2015.

Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca's drug is administered with a pressurized meter-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
AstraZeneca said on Wednesday its experimental lung drug PT003 for chronic lung disease had proved successful in two final-stage Phase III trials. The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago,combines a long-acting beta-2 agonist (LABA)...
lung, disease, drug, astrazeneca, pt1003
90
2015-34-18
Wednesday, 18 Mar 2015 08:34 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved